[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT05477004":3,"trial-entities:NCT05477004":83,"trial-summary:NCT05477004":90},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":27,"primary_purpose":15,"phases":28,"enrollment_info":29,"interventions":32,"primary_outcomes":41,"secondary_outcomes":46,"sex":50,"minimum_age":51,"maximum_age":15,"healthy_volunteers":52,"eligibility_criteria":53,"std_ages":63,"locations":66,"central_contacts":76,"overall_officials":77,"references":81,"see_also_links":82},"NCT05477004","62561","Observational Study of Ketamine Infusions for the Treatment of Chronic Pain","Ketamine Infusion for the Treatment Chronic Pain in Adults: a Prospective Observational Study to Characterize Predictors and Outcomes","ENROLLING_BY_INVITATION","2026-12-31","2025-12","2025-12-19","2022-06-01","Theresa Lii","OTHER",null,"This observational study will collect prospectively specified data on patient characteristics and clinically relevant outcomes in patients who receive a ketamine infusion at Stanford Pain Management Center for the treatment of chronic pain, with the goal of identifying treatment responders and relationships between patient characteristics and treatment response.","Ketamine is a type of anesthetic drug which has been used off-label to treat chronic pain. The effectiveness of intravenous ketamine and its duration of effect are not well-understood. There is high variability in response to ketamine, and it remains unclear which patient characteristics are associated with favorable outcomes. This observational study will collect a wide range of patient-reported outcomes via digital surveys: once at baseline before treatment, and up to 7 follow-up surveys for up to 12 months following a single ketamine infusion. Survey data will be supplemented by clinical data obtained from electronic medical records.",[19],"Chronic Pain",[21,22,23,24,25,26],"ketamine","chronic pain","pain syndrome","neuropathic pain","complex regional pain syndrome","intractable pain","OBSERVATIONAL",[],{"count":30,"type":31},100,"ESTIMATED",[33],{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":39},"DRUG","Ketamine","A multi-day continuous ketamine infusion delivered intravenously at subanesthetic doses in a monitored setting",[38],"Open label ketamine",[40],"Ketalar",[42],{"measure":43,"description":44,"timeFrame":45},"Change from baseline Patient Global Impression of Change (PGIC) in overall status; measured with PGIC Scale","The PGIC Scale is a single-question 7-point Likert scale ranging from \"Very much improved\" to \"Very much worse.\"","1 week, 2 weeks, 1 month, 2 months, 3 months, 6 months, 12 months (or up to the time of their next ketamine infusion)",[47],{"measure":48,"description":49,"timeFrame":45},"Change from baseline average pain intensity; measured with Numeric Rating Scale (NRS)","Participants rate their average pain intensity over the last 7 days using whole numbers on a 0-to-10 scale, with higher values indicative of more pain.","ALL","18 Years",false,{"inclusion":54,"exclusion":60,"raw_text":62},[55,56,57,58,59],"Has been seen at Stanford's Pain Management Center for a doctor's visit at least once.","Is scheduled to undergo at least 1 ketamine infusion for the treatment of any chronic pain condition.","Have a valid email address and consents to receiving surveys by email.","Able to read, understand, and respond to English-language surveys on an electronic device such as a cell phone, tablet, or computer.","Able to read, understand, and provide written, dated informed consent.",[61],"Has their ketamine infusion cancelled, which may occur before or after consenting to this study.","Inclusion Criteria:\n\n* Has been seen at Stanford's Pain Management Center for a doctor's visit at least once.\n* Is scheduled to undergo at least 1 ketamine infusion for the treatment of any chronic pain condition.\n* Have a valid email address and consents to receiving surveys by email.\n* Able to read, understand, and respond to English-language surveys on an electronic device such as a cell phone, tablet, or computer.\n* Able to read, understand, and provide written, dated informed consent.\n\nExclusion Criteria:\n\n* Has their ketamine infusion cancelled, which may occur before or after consenting to this study.",[64,65],"ADULT","OLDER_ADULT",[67],{"facility":68,"city":69,"state":70,"zip":71,"country":72,"geoPoint":73},"Stanford University","Stanford","California","94305","United States",{"lat":74,"lon":75},37.42411,-122.16608,[],[78],{"name":79,"affiliation":68,"role":80},"Theresa Lii, MD","PRINCIPAL_INVESTIGATOR",[],[],{"nct_id":4,"conditions":84,"biomarkers":89},[19,85,86,87,88],"Complex Regional Pain Syndrome","Intractable Pain","Neuropathic Pain","Paine syndrome",[],{"nct_id":4,"found":52,"summary":15,"prompt_version":15}]